Kadrmas Dan J, Kemp Brad J, Sitek Arkadiusz, Chareonthaitawee Panithaya
MultiFunctional Imaging LLC, South Ogden, UT, USA.
Mayo Clinic, Rochester, MN, USA.
J Nucl Cardiol. 2025 Aug;50:102268. doi: 10.1016/j.nuclcard.2025.102268. Epub 2025 Jun 9.
F-flurpiridaz is the newest positron emission tomography myocardial perfusion tracer approved in the US for evaluating myocardial ischemia and infarction (Flyrcado™, GE HealthCare). The 110 minutes half-life of F enables flurpiridaz to be made and shipped regionally; however, it also results in high levels of residual tracer activity for same-day rest/stress scanning. This study provides a technical evaluation of immediate back-to-back rest/stress flurpiridaz positron emission tomography (PET) with no delay, using a commercially available software medical device (mfiVerse™, MultiFunctional Imaging LLC) to correct for residual activity effects.
Retrospectively obtained separate-scan dynamic rest and pharmacologic stress flurpiridaz images in 11 subjects were digitally shifted and combined to model a 15 minute rest/stress procedure with rest scan from 0 to 8 minutes and stress scan from 8 to 15 minutes, providing a paired-sample study design. The modeling of residual tracer effects included both distributed activity and stress effects upon residual arterial input. Residual activity biased mean stress pixel values and myocardial blood flow (MBF) by +31% and +64%, respectively, as compared with the reference stress images without residual activity. These biases were each reduced to less than 1% after residual activity correction. Linear regression analysis found that corrected stress pixel values (r = .998) and MBF (r = .994) closely matched reference stress values, both being equivalent to separate-scan values to less than half of test-retest variability (P < .001). Summed stress scores averaged 2.5 points lower for uncorrected images versus the reference images, and averaged .4 points lower after correction.
Within the study limitations, these results demonstrate that rest and stress flurpiridaz PET images can be obtained immediately back-to-back without rest-stress delay when accurate correction for residual activity is performed.
F-氟吡哒唑是美国批准用于评估心肌缺血和梗死的最新正电子发射断层扫描心肌灌注示踪剂(Flyrcado™,通用电气医疗集团)。F的110分钟半衰期使得氟吡哒唑能够在当地制备和运输;然而,这也导致同日静息/负荷扫描时残留示踪剂活性水平较高。本研究使用市售软件医疗设备(mfiVerse™,多功能成像有限责任公司)校正残留活性影响,对无延迟的即时背靠背静息/负荷氟吡哒唑正电子发射断层扫描(PET)进行技术评估。
回顾性获取11名受试者的单独扫描动态静息和药物负荷氟吡哒唑图像,进行数字移位并合并以模拟15分钟的静息/负荷程序,静息扫描从0至8分钟,负荷扫描从8至15分钟,提供配对样本研究设计。残留示踪剂效应的建模包括分布活性和负荷对残留动脉输入的影响。与无残留活性的参考负荷图像相比,残留活性使平均负荷像素值和心肌血流量(MBF)分别偏差+31%和+64%。残留活性校正后,这些偏差均降至1%以下。线性回归分析发现,校正后的负荷像素值(r = 0.998)和MBF(r = 0.994)与参考负荷值紧密匹配,两者均相当于单独扫描值,小于重测变异性的一半(P < .001)。未校正图像的总负荷评分平均比参考图像低2.5分,校正后平均低0.4分。
在研究局限性范围内,这些结果表明,当对残留活性进行准确校正时,可立即背靠背获取静息和负荷氟吡哒唑PET图像,无需静息-负荷延迟。